Adequate Initial Heparin Dosage for Atrial Fibrillation Ablation in Patients Receiving Non-Vitamin K Antagonist Oral Anticoagulants

25Citations
Citations of this article
91Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background and Objective: During atrial fibrillation ablation, heparin is required and is guided by the activated clotting time (ACT). Differences in the ACT before ablation and adequate initial heparin dosing in patients receiving non-vitamin K antagonist oral anticoagulants (NOACs) were examined. Methods: Patients who received warfarin (control, N = 90), dabigatran etexilate (N = 90), rivaroxaban (N = 90) and apixaban (N = 90) were studied. A 100 U/kg dose of heparin was administered as a reliable control dose for warfarin, and the remaining patients were randomly administered 110, 120 or 130 U/kg of heparin in each NOAC group, followed by a continuous heparin infusion. Results: Periprocedural thromboembolic and major bleeding were not observed. Minor bleeding occurred rarely without significant differences among the groups examined. Baseline ACTs were longer in the warfarin (152 ± 16 s) and dabigatran (153 ± 13 s) groups than in the rivaroxaban (134 ± 13 s) and apixaban (133 ± 20 s) groups. The initial bolus heparin dosages required to produce an ACT 15 min after the initial bolus that was identical to the control (333 ± 32 s) were 120 U/kg (318 ± 29 s) and 130 U/kg (339 ± 43 s) for dabigatran, 130 U/kg (314 ± 31 s) for rivaroxaban and 130 U/kg (317 ± 39 s) for apixaban. The NOAC groups required significantly larger doses of total heparin than the warfarin group. Conclusion: The baseline ACTs differed among the three NOAC groups. The results of the comparison with warfarin (the control) indicated that dosages of 120 or 130 U/kg for dabigatran, and 130 U/kg for rivaroxaban and apixaban, were adequate initial heparin dosages.

References Powered by Scopus

Dabigatran versus warfarin in patients with atrial fibrillation

9793Citations
N/AReaders
Get full text

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation

8166Citations
N/AReaders
Get full text

Apixaban versus warfarin in patients with atrial fibrillation

7726Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Activated clotting time monitoring during atrial fibrillation catheter ablation: Does the anticoagulant matter?

29Citations
N/AReaders
Get full text

Management of intraprocedural anticoagulation in patients on non-Vitamin K antagonist oral anticoagulants undergoing catheter ablation for atrial fibrillation understanding the gaps in evidence

20Citations
N/AReaders
Get full text

Higher incidence of asymptomatic cerebral emboli after atrial fibrillation ablation found with high-resolution diffusion-weighted magnetic resonance imaging

19Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Yamaji, H., Murakami, T., Hina, K., Higashiya, S., Kawamura, H., Murakami, M., … Kusachi, S. (2016). Adequate Initial Heparin Dosage for Atrial Fibrillation Ablation in Patients Receiving Non-Vitamin K Antagonist Oral Anticoagulants. Clinical Drug Investigation, 36(10), 837–848. https://doi.org/10.1007/s40261-016-0435-6

Readers over time

‘16‘17‘18‘19‘20‘21‘22‘23‘24‘2507142128

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 27

69%

Researcher 7

18%

Professor / Associate Prof. 3

8%

Lecturer / Post doc 2

5%

Readers' Discipline

Tooltip

Medicine and Dentistry 30

63%

Pharmacology, Toxicology and Pharmaceut... 13

27%

Biochemistry, Genetics and Molecular Bi... 3

6%

Nursing and Health Professions 2

4%

Save time finding and organizing research with Mendeley

Sign up for free
0